ArriVent BioPharma, Inc. 8-K

What Happened
ArriVent BioPharma, Inc. filed a Form 8-K on May 11, 2026 to announce a Prospectus Supplement (dated May 11, 2026) for its existing at-the-market (ATM) offering program. Under the Prospectus Supplement, the company may offer and sell common stock having an aggregate offering price of up to $250,000,000 from time to time through Jefferies LLC as sales agent pursuant to the Open Market Sale Agreement dated February 3, 2025. The Prospectus Supplement was filed under the company’s automatic shelf registration statement on Form S-3ASR (File No. 333-284661).

Key Details

• Date filed: May 11, 2026 (Prospectus Supplement dated May 11, 2026).
• Offering size: up to $250,000,000 of common stock on an at-the-market basis.
• Sales agent: Jefferies LLC, under the Open Market Sale Agreement dated February 3, 2025.
• Registration: Filed under the company’s Form S-3ASR registration statement (File No. 333-284661); legal opinion of Mintz Levin is included as an exhibit.

Why It Matters
An ATM offering lets ArriVent raise capital gradually by selling shares into the open market when market conditions are favorable. For investors, this is important because future share sales under the ATM could increase the number of outstanding shares and may affect share price and ownership percentages. The filing itself does not announce any immediate share sales or specific use of proceeds—rather, it establishes the company’s ability to raise up to $250 million through this program. Investors should monitor future SEC filings (e.g., 8-Ks or prospectus supplements) for actual sales activity and any disclosures about how proceeds will be used.